Iridex Reports 7 Percent Q2 Revenue Gain
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 13 2025
0mins
Source: Fool
Financial Performance: Iridex reported a 7% year-over-year revenue increase to $13.6 million for Q2 2025, with improved earnings per share and reduced operating expenses leading to a narrower net loss and positive non-GAAP adjusted EBITDA, despite concerns over declining gross margins.
Business Strategy: The company is focusing on cost control, operational discipline, and increasing sales of recurring-use consumables, while facing challenges in its Cyclo G6 product family sales; management aims for cash flow breakeven and sustained profitability without significant new revenue growth forecasts.
Discover Tomorrow's Bullish Stocks Today
Receive free daily stock recommendations and professional analysis to optimize your portfolio's potential.
Sign up now to unlock expert insights and stay one step ahead of the market trends.
Analyst Views on IRIX
About IRIX
IRIDEX Corporation is an ophthalmic medical technology company. The Company is developing, manufacturing, and marketing versatile laser-based medical systems, delivery devices and consumable instrumentation. Its MicroPulse Technology and Endpoint Management Technology are used for the treatment of glaucoma and retina disorders. Its laser consoles product consists of Glaucoma, Medical Retina and Surgical Retina. Its glaucoma console line is the Cyclo G6 laser system with MicroPulse technology. Its surgical-retina product line includes its OcuLight TX and OcuLight SLx laser photocoagulation systems. Its medical-retina product line includes its portable IQ 532 and IQ 577 laser systems. Its laser probe products include Glaucoma and Surgical Retina. Probes used in its glaucoma product line include its patented single-use delivery devices-MicroPulse P3, G-Probe, and G-Probe Illuminate. Probes used in its surgical retina product line include its family of single-use EndoProbe handpieces.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Iridex's MicroPulse Technology Effectively Lowers Intraocular Pressure in Glaucoma Patients
- Clinical Study Results: An independent study at the University Eye Clinic Maastricht shows that retreatment with MicroPulse laser treatment (MicroPulse TLT) reduces intraocular pressure (IOP) by 25% to 35% in glaucoma patients, demonstrating the technology's effectiveness and safety in glaucoma management.
- Treatment Flexibility: The study involved 76 eyes, with retreatment timing varying from approximately 4 months to over 28 months, showcasing the individualized management capabilities of the technology, allowing for flexible treatment adjustments based on patient responses.
- Success Rate of Repeat Treatments: Results indicate that patients who initially benefited from treatment have higher long-term success rates upon retreatment, aiding clinicians in better identifying candidates for retreatment and optimizing glaucoma management strategies.
- Company Strategic Commitment: Iridex CEO Patrick Mercer stated that the findings further validate MicroPulse TLT as a valuable non-incisional option, reflecting the company's strong commitment to advancing clinical evidence and supporting ophthalmologists in delivering durable outcomes for their patients.
Continue Reading
Iridex Publishes Study on Thermal Dynamics of Laser Treatments for Glaucoma
- Research Findings: Iridex's newly published study provides the first quantitative comparison of thermal tissue effects between CW-TSCPC and MicroPulse TLT, revealing that CW-TSCPC creates a 2 mm thermal zone exceeding 100°C for 2.2 seconds, indicating potential risks in glaucoma treatment.
- Technical Advantages: MicroPulse TLT generates a smaller thermal zone of 0.6-1.2 mm with peak temperatures below 100°C, demonstrating its safety and uniform heat distribution, which may offer a safer option for earlier interventions.
- Clinical Significance: The study underscores the thermal continuum between the two techniques, suggesting that with further optimization, they could serve complementary roles in glaucoma management, enhancing treatment diversity.
- Company Commitment: Iridex CEO Patrick Mercer highlighted that this research reflects the company's commitment to evidence-based innovation in glaucoma care, aiming to improve treatment outcomes through a deeper understanding of laser interactions with ocular tissues.
Continue Reading